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Mental Health Research Institute and Departments of Bwl&al Chemrsrry and 
Aychiatty, Univmity ofMichigan, Ann Arbor, Michigan, USA 
ABSTRACT The past decade has witnessed an enormous increase in our knowl- 
edge of the variety and complexity of intracellular signaling events that follow 
receptor binding on the cell surface. This overview emphasizes the phosphoinosi- 
tidase C-mediated dual messenger pathway in brain and in brain-derived cells, 
with special reference to possible significance for research on the dementia. 
INTRODUCTION 
The metabolic rate of the human brain is high, accounting for some 
20-25% of the body’s energy consumption at rest, even though it represents 
only about 2% of total body mass. This remarkable energy requirement is a 
reflection of the excitable nature of nervous tissue, That is, it is metabolically 
costly to maintain the ability to rapidly conduct impluses within neurons and 
to mediate chemically transmitted signals between them. While neurotrans- 
mitter synthesis, storage and release all require ATP, some of the brain’s 
metabolic expense can be attributed to the sequence of intracellular signaling 
events that occur between neurotransmitter binding to extracellular receptors 
and the ultimate physiological expression of the message, eg., initiation or 
block of secretion, of muscular contraction, of nerve impulse generation or 
of genomic processing. As these intramembrane and cytosolic chemical mes- 
sengers are identified, convergence on intracellular Ca2 + regulation and pro- 
tein kinases and phosphatases becomes increasingly apparent. A central role 
in intracellular signaling is evident for the dual pathway initiated by the phos- 
phodiesteratic cleavage of phosphatidylinositol4,5-bisphosphate (PIP*) into 
two moieties, each of which then serves as an intracellular messenger: inositol 
1,4,5-trisphosphate (1,4,5-IP3) and 1,2-diacyl-sn-glycerol (DAG). This re- 
ceptor-stimulated, G-protein-mediated cleavage is catalyzed by a phosphoino- 
sitide-specific phospholipase C (phosphoinositidase C; PLC). One turn of 
the “phosphoinositide cycle” whereby PIP2 is regenerated consumes at least 
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TABLE 1." Neural Receptors That Activate Phosphoinositidase C-mediated 
Cleavage of PIP2 
~ ~~~ ~~ 
Muscarinic cholinergic (MI and MJ) 
Brain slices, retina, cochlea, primary neuronal cultures, neuroblastoma cells (SK-N-SH and 
SH-SY-5Y), astrocytoma cells (1321N1), glioma cells (c6), neuroepithelioma cells (SK- 
N-MC), pheochromocytoma cells (PC-12) 
Adrenergic (am and am) 
Histaminergic (HI) 
Serotonergic (5HT2 and 5HTlc:) 
Glutamatergic (metabotropic) 
Endothelin 
Brain slices, primary neurond and primary glial cultures, SK-N-MC cells, c6 cells 
Primary gkd cultures, neuroblastoma cells (NIE-l15), c6 cells 
Brain (in vivo), brain slices, primary neuronal cultures, pituitary tumor cells (P1 l), c6 cells 
Brain slices, retina, synaptoneurosomes, primary glial cultures 
Brain slices, primary neuronal and primary glial cultures, glial cells (C,  and SK-N- 
MC cells 
Above, brain receptor ligands that mediate a robust stimulation of phosphoinositide turnover 
in neural tissues, generally demonstated by means of preincubation of the listed preparations 
with 3H-inositol. and measurement of accumulated labeled inositol phosphates following further 
incubation in the presence of the ligand and Li + . Somewhat reduced stimulation is evoked in 
neural tissues by a number of additional ligands, for which principal evidence of a phosphoinosi- 
tide-linkage comes from studies in non-neural tissues. They include: purinergic ( Pz), thrombox- 
ane (Az), nerve growth factor, prostaglandin (Ez), bradykinin (Bz), vasopressin (Vl) ,  cholecys- 
tolunin, neuropeptide Y, neurotensin, gastrin-releasing peptide, bombesin, substance P. 
oxytocin, eledoisin. neurokinin, vasointestinal peptide, angiotensin, gonadotropin-releasing hor- 
mone, platelet activating factor, and thyrotropin releasing hormone. 
From ref. 1, in which specific literature references for each example may be found. 
5 high energy phosphate equivalents. Given the large and growing list of 
ligands shown to bind to receptors that utilize the ligand-stimulated PLC 
pathway (TABLE l ) ,  we may consider that operation of the pathway and its 
associated cellular functions likely accounts for a significant fraction of total 
brain metabolism. This complex dual pathway is of great interest, not only 
because its elucidation will lead to a better understanding of normal brain 
function, but also for the possibility that such understanding will then lead 
to the discovery of correlates of the dementias. 
BIOCHEMICAL ASPECTS OF THE PHOSPHOINOSITIDE CYCLE 
The three phosphoinositidcs, phosphatidylinositol (PI), phosphatidylino- 
sitol4-phosphate (PIP) and PIP2 are a family of quantitatively minor compo- 
nents of eukaryotic membrane lipids, of which PI, the metabolic precursor 
of PIP and PIP2, is by far the most prevalent. The phosphoinositides are the 
most acidic of the phospholipids and are synthesized by the cytidinc 
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diphosphodiacylglycerol (CDP-DAG) pathway, as are the phosphatidylglyc- 
erol series of mitochondrial lipids. The cyclic sequence of reactions whereby 
phosphoinositide is broken down and regenerated is catalyzed by six enzymes, 
two of which are unique to the stimulated turnover, while the remaining 
four also mediate de novo synthesis. The latter are CDP-DAG synthase, PI 
synthase, PI kinase, and PI 4-kinase. One of the two turnover-specific steps 
is catalyzed by PLC, initiating the cycle of breakdown and resynthesis. DAG 
released upon PIP2 cleavage is phosphorylated via DAG kinase to phosphati- 
date (PA), which in turn serves as substrate for CDP-DAG synthesis, thence 
to PI, PIP and PIP2, completing the cycle. 
Studies in brain and in other tissues indicate the presence of many isoforms 
of PLC, based upon purification and characterization on the one hand, and 
upon established amino acid sequence, on the other. The differences in func- 
tion of various PLC families thus far identified are not yet certain, but it is 
clear that some isoforms are regulated by G-proteins (and can in turn regulate 
G-proteins by serving as GTPase-activating proteins), while others are regu- 
lated by tyrosine k i n a ~ e s . ~ . ~  
DAG kinase may regulate the cycle in a number of ways. By phosphorylat- 
ing DAG, it can serve as an “off signal that deactivates protein kinase C 
(PKC). The product, PA, has been reported to stimulate PIP 4-kinase activ- 
ity.* A membrane-bound DAG kinase activity has been described that is 
highly selective for the 1-stearoyl, 2-arachidonoyl species of DAG that charac- 
terizes all six of the phosphoinositide cycle lipids, and may play a crucial role 
in isolating this unique DAG species from other cellular DAG pools, such 
as those seen in phosphatidylcholine or phosphatidylethanolamine synthesis 
and breakd~wn.~  We have found that the essential fatty acid arachidonate 
(20:4w6ck) is deficient in standard cell culture media‘ and is largely replaced 
by “Mead” acid (20 : 309ck). Cells grown on the deficient media appear nor- 
mal and show no deficit in phosphoinositide signaling. Since the fatty acid 
composition of the DAGs has generally been found to have relatively little 
effect on the DAG’s activation of PKC, the effects of arachidonate supplemen- 
tation on such depleted cells may be usehl for investigation of the physiologi- 
cal significance of reported interactions of arachidonate metabolites with the 
PLC-mediated pathway, as well as with cyclic AMP and other second messen- 
ger ~ys tems.~  Similarly, dietary restriction of arachidonate should decrease 
prostanoid production, but as a result of these cell culture studies, is predicted 
to have little effect on phosphoinositide-mediated signaling. This observation 
could be of value in dietary approaches to lowering prostanoid formation in 
Vivo. 
OTHER BRAIN INOSITOL LIPIDS 
A variety of proteins are bound to all membranes via a PI anchor, in 
which the 6-position of inositol is glycosylated. The carbohydrate substituent, 
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containing glucosamine and mannose, is linked to the protein via ethanol- 
amine. While phospholipse C does not act on these lipids, PI anchor-degrad- 
ing phospholipases have been found in brain. 
A family of polyphosphoinositides has been described, primarily in non- 
neural tissues, in which PI is phosphorylated on the 3 rather than on the 4 
position of inositol to form PI3P, PI(3,4)Pz and PI(3,4,5)P3. Roles for these 
trace lipids in neural function have not yet been indicated, but can be antici- 
pated, since brain has proven to be an excellent source of PI 3-kinase. 
RELEVANCE TO THE DEMENTIAS 
A number of investigations, using animal models, postmortem human 
brain or cultured human cells have been employed to examine the possible 
involvement of the stimulated PLC pathway in Alzheimer’s disease. Since a 
quantitatively major fraction of the brain’s PLC-linked receptors are thought 
to be muscarinic cholinergic, and further, since defects in acetylcholine metab- 
olism have long been implicated in Alzheimer’s disease, there have been nu- 
merous investigations on a possible link between the disease and the stimu- 
lated PLC pathway. Recent examples include studies in cells tranfected with 
human brain muscarinic receptors, in which cholinergic stimulation alters 
amyloid precursor protein metabolism, presumably via PKC activation.8 
From studies in rats and in GTP,S-supplemented postmortem human brain 
membranes, Crews et d9 conclude that amyloid P-protein may selectively 
block cholinergic and serotonergic PLC-mediated signal transduction. Com- 
paring cultured fibroblasts from Alzheimer’s disease patients with those of 
age-matched control patients, Gibson’s laboratory has reported evidence for 
differences in available intracellular Ca2+ pools in the two cell populations, 
based on bradykinin receptor-stimulated, PLC-mediated release of 1,4,5-IP3, 
together with the effects of ionophores and of other agents.’O 
Whether these studies will lead to a common causal mechanism, or  to 
biological markers of the disease or of its progression, they may well constitute 
an important step forward in our understanding of the underlying pathologic 
process, and put us on firmer ground in proposing possible therapeutic inter- 
ventions. 
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